Compare Amphastar Pharmaceuticals Inc (AMPH) vs Huntington Bancshares Incorporated (HBAN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Huntington Bancshares Incorporated — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Huntington Bancshares Incorporated trades at $17.89 (market cap $36.22B). The key difference: Huntington Bancshares Incorporated is far larger — about 43.8× Amphastar Pharmaceuticals Inc's market cap, and Huntington Bancshares Incorporated pays a 3.47% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | HBAN | |
|---|---|---|
Market Cap | $826.08M | $36.22B |
Sector | Health | Financials |
52-Week High | $30.81 | $19.27 |
52-Week Low | $16.87 | $15.02 |
Enterprise Value | $1.22B | — |
Dividend Yield | — | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
HBAN trades at $17.87, up 0.62% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.25. Recent Q1 2026 earnings beat expectations with EPS of $0.26, and revenue for 2025 grew to $8.13B. The company maintains a solid net income margin of 25.13% and a P/E ratio of 13.75, indicating reasonable valuation. News highlights include expansion in Texas and a recent dividend payment, supporting positive sentiment.
The outlook for HBAN is positive, with growth driven by strategic acquisitions and organic loan expansion, though risks include integration challenges and competitive pressures in regional banking. Analysts are predominantly bullish, with 49% recommending buy, suggesting potential upside from current levels if earnings targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →
